Evidence map›Paper›PMID 38914910›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2024

An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies.

Csaba B Kátai, Shepard J Smithline, Craig J Thalhauser, Sieto Bosgra, Jeroen Elassaiss-Schaap

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Csaba B KátaiPD-value B.V., Yalelaan 1, 3584, Utrecht, CL, The Netherlands. csaba@pd-value.com.
Shepard J SmithlineGenmab US, Inc., 777 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Craig J ThalhauserGenmab US, Inc., 777 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Sieto BosgraGenmab B.V., Uppsalalaan 15, 3584, Utrecht, CT, The Netherlands.
Jeroen Elassaiss-SchaapPD-value B.V., Yalelaan 1, 3584, Utrecht, CL, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A basic FcRn-regulated clearance mechanism is investigated using the method of matched asymptotic expansions. The broader aim of the work is to obtain further insight on the mechanism, thereby providing theoretical support for future pharmacologically-based pharmacokinetic modelling efforts. The corresponding governing equations are first non-dimensionalised and the order of magnitudes of the model parameters are assessed based on their values reported in the literature. Under the assumption of high FcRn-binding affinity, analytical approximations are derived that are valid over the characteristic phases of the problem. Additionally, relatively simple equations relating clearance and AUC to physiological model parameters are derived, which are valid over the longest characteristic time scale of the problem. For lower to moderate doses clearance is effectively linear, whereas for higher doses it is nonlinear. It is shown that for all doses sufficiently high the leading-order approximation for the IgG concentration in plasma, over the longest characteristic time scale, is independent of the initial dose. This is because IgG that is in 'excess' of FcRn is eliminated over a time scale much shorter than that of the terminal phase. In conclusion, analytical approximations of the basic FcRn mechanism have been derived using matched asymptotic expansions, leading to a simple equation relating clearance to FcRn binding affinity, the ratio of degradation and FcRn concentration, and the volumes of the system.

Indexed as

Histocompatibility Antigens Class IModels, BiologicalReceptors, FcArea Under CurveHumansImmunoglobulin GMetabolic Clearance RateProtein BindingFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GReceptors, FcFcRn salvagemAbPBPKPerturbation theory

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.